

Sheet



of

1

3

PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031

104322.198

Under the Paperwork Reduction Act of 1995, no persons are required to re	Patent and Trader	mark Office: U.S. DEPARTMENT OF Co on unless it contains a valid OMB contro	OMMERCE
Substitute for form 1449A/PTO		C mpl te if Known	Ta La
INFORMATION PIGGL COURT	Application Number		<u></u>
INFORMATION DISCLOSURE	Filing Date	HEREWITH	<b>"</b> :=
STATEMENT BY APPLICANT	First Named Inventor	Chari	<del>- 2</del> 9
	Group Art Unit	1642	<u></u>
(use as many sheets as necessary)	Evaminer Name	PAWITHAD	هن م

Attorney Docket Number

	U.S. PATENT DOCUMENTS								
Examiner Initials*	No.1	U.S. Patent Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
SR.	4	5,208,02	20	Chari et al	05-04-1993				
				- "					
			<del> </del>						
			h						
					-				

				FOI	REIGN PATENT DOCUMENT	S		
Examiner	Cite	ļ. r	oreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	1e	
								$oldsymbol{oldsymbol{oldsymbol{\sqcup}}}$
								$oldsymbol{oldsymbol{\sqcup}}$
								$\bot$
								$\bot$
					<b>_</b>			<b></b>
	-							-
								<del></del>
								Щ.

Examiner 1 2 Signature	Date Considered	5/5-102
------------------------	--------------------	---------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box + Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449B/PTO	)		Co	ompl te if Known
				Application Number	
INFO	DRMATION	DI	ISCLOSURE	Filing Date	HEREWITH
STA	TEMENT B	Y.	APPLICANT	First Named Inventor	Chari
• • • • • • • • • • • • • • • • • • • •		•		Group Art Unit	1642
	(use as many st	heets	as necessary)	Examiner Name	RANLINGS
Sheet	2	of	3	Attomey Docket Number	104322.198

Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	publisher, city and/or country where published.	
8	ImmunoGen, Inc. Press Release (February 25, 1999).	7
c	Apelgren et al, Cancer Research, 50:3540-3544 (1990).	
D	Bai et al, Cancer Research, 56:4398-4406 (1996).	
E	Dieras et al, 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, page 100, Abstract Nos. 382 and 383 (June 1998).	
F	Glisson et al, Journal of Clinical Oncology, 17(8):2309-2315 (August 1999).	
G	Griffin et al, The Journal of Immunology, 130(6):2947-2951 (1983).	7
Н	Kibbelaar et al, Journal of Pathology, 159:23-28 (1989).	7
I	Laguzza et al, J. Med. Chem., 32:548-555 (1989).	
ナ	Liu et al, Proceedings of the American Association for Cancer Research, 38:29 Abstract No. 190 (1997).	7
К	Liu et al, Proc. Natl. Acad. Sci. USA, 93:8618-8623 (1996).	
L	Morris et al, Journal of Clinical Oncology, 16(3):1094-1098 (March 1998).	
	D F G H I	Dieras et al, 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, page 100, Abstract Nos. 382 and 383 (June 1998).  Glisson et al, Journal of Clinical Oncology, 17(8):2309-2315 (August 1999).  Griffin et al, The Journal of Immunology, 130(6):2947-2951 (1983).  Kibbelaar et al, Journal of Pathology, 159:23-28 (1989).  Laguzza et al, J. Med. Chem., 32:548-555 (1989).  Liu et al, Proceedings of the American Association for Cancer Research, 38:29 Abstract No. 190 (1997).  Liu et al, Proc. Natl. Acad. Sci. USA, 93:8618-8623 (1996).

Examiner Signature	12	Date Considered	5/5/02
Olgitature		Considered	THE PARTY NAMED IN COLUMN TO SERVICE AND ADDRESS OF THE PARTY NAMED IN

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-96)

Please type a plus sign (+) inside this box

Appress for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449B/PTO	ı		Complete if Known				
				Application Number				
INFO	PRMATION	D	SCLOSURE	Filing Date	HEREWITH			
STA	TEMENT B	Y	APPLICANT	First Named Inventor	Chari			
017		•	AI I LIOAIII	Group Art Unit	1642			
	(use as many sl	heets	as necessary)	Examiner Name	RAWLINGS			
Sheet	3	of	3	Attorney Docket Number	104322.198			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
SR	М	Panda et al, Proc. Natl. Acad. Sci. USA, 95:9313-9318 (August 1998).	
SP	٨	Pitot et al, Clinical Cancer Research, 5:525-531 (March 1999).	1
8R	O	Pettit et al, J. Am. Chem. Soc., 111:5463-5465 (1989).	
SR	P	Roguska et al, Protein Engineering, 9(10):895-904 (1996).	
SR	Q	Roguska et al, Proc. Natl. Acad. Sci. USA, 91:969-973 (1994).	
SR	R	Rygaard et al, Br. J. Cancer, 65:573-577 (1992).	1.
5°R	S	Schrappe et al, Cancer Research, 52:3838-3844 (1992).	_
SR	T	Smith et al, Cancer Research, 54:3779-3784 (1994).	
Sr	И	Villalona-Calero, Journal of Clinical Oncology, 16(8):2770-2779 (August 1998).	
SE	٧	Doria et al, Cancer 62:1939-1945 (1988).	

Examin r	pn	Dat	575-102
Signature	//	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEFARTMENT OF COMMERCE

alo i apci	WORK INCUMONION TOOL OF	1000, 1	to persons of diodenico to rosp	TOURS IN THE PRODUCT OF THE PROPERTY	Tuniess it contains a valid Civib control number.
Substitu	ute for form 1449B/PTO	)	& TRADEMA	Co	omplete if Known
				Application Number	09/671,995
INF	ORMATION	DI	SCLOSURE	Filing Date	September 29, 2000
STA	TEMENT B	Y	APPLICANT	First Named Inventor	Chari
•		• •		Group Art Unit	1642
	(use as many sh	neets a	as necessary)	Examiner Name	M. Transa RAWLINGS
Chook	1	of	-	Attorney Docket Number	704200 100

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ2
SR	W	Liu et al, Proc. Natl. Acad. Sci. USA, 93:8618-8623 (August 1996).	
5R	×	Embleton et al, Br. J. Cancer, 47:043-049 (1993).	
2K	У	Mendelsohn et al, Clin. Cancer Res., 3:2703-2707 (December 1997).	
25	7	Ghaemmaghami et al, Chest, 113(Supp. 1):86s-91s (January 1998).	
SR	ΛA	Christian et al, Gynecologic Oncology, 55:s143-s150 (1994).	

Examiner		Date	5/5/02	
Signature	7	Considered	5/0/02	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any conthe amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, TDO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and r considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.